Addison's Disease: History and Discovery

Addison's disease — the slow, once-fatal failure of the adrenal glands — is named for the London physician Thomas Addison, who in his 1855 monograph On the Constitutional and Local Effects of Disease of the Supra-renal Capsules was the first to connect a distinctive clinical picture (wasting, weakness, low blood pressure, and a striking bronzing of the skin) to destruction of the small glands sitting atop the kidneys. A brief note in 1849 had foreshadowed the work. The condition was christened “Addison's disease” by the French physician Armand Trousseau. For nearly a century the leading cause was tuberculosis of the adrenals; today, in the developed world, the leading cause is autoimmune destruction of the gland. What was uniformly fatal in Addison's day became survivable only after the adrenal hormone cortisone was isolated and synthesized — work recognized by the 1950 Nobel Prize. This page traces that arc, verifying each name, date, and “first” against the historical record.

The Adrenal Glands Before 1855
Thomas Addison and the 1855 Monograph
Trousseau and the Naming of the Disease
Tuberculosis versus Autoimmune Causes Over Time
The Hormone-Replacement Revolution
The Evolution of Diagnosis
Modern Understanding
Legacy and a Famous Patient
Research Papers and References
Connections

The Adrenal Glands Before 1855

The two small glands that cap the kidneys were anatomically known long before anyone understood what they did. They are generally credited as having been first described by the Italian anatomist Bartolomeo Eustachi in the mid-sixteenth century, who depicted them in his anatomical plates. For the next three hundred years, however, the “suprarenal capsules” (also called the supra-renal or adrenal glands) were a physiological puzzle. They had no obvious duct, so they were not glands of the familiar secreting kind; anatomists speculated variously that they cushioned the kidneys, drained fluid, or served some role in fetal life that lapsed in the adult.

Because their function was unknown, disease of the adrenal glands was essentially invisible to medicine. A patient might waste away, weaken, and darken in colour, and die without anyone connecting those events to the two unremarkable bodies found shrunken or diseased at autopsy — if they were examined at all. There was no framework in which adrenal failure could even be a recognized diagnosis. This is the crucial backdrop to Addison's achievement: he was not refining an existing disease category but assembling one for the first time, from scattered bedside observations and post-mortem findings, in an era with no hormone concept and no blood tests.

Back to Table of Contents

Thomas Addison and the 1855 Monograph

Thomas Addison (c. 1793–1860) was one of the celebrated diagnosticians of Guy's Hospital in London, where he taught and practised from the 1820s until shortly before his death. A formidable bedside observer and morbid anatomist, he is remembered today as one of the “great men of Guy's,” alongside his contemporaries Richard Bright and Thomas Hodgkin. Addison's name is in fact attached to two distinct conditions: Addison's disease (adrenal insufficiency) and Addisonian (pernicious) anaemia — it was while investigating the latter that he encountered the diseased adrenal glands that launched the work below.

Addison made a brief preliminary announcement in 1849, in the London Medical Gazette, noting changes in the suprarenal capsules. The full, careful statement came six years later in his short but landmark 1855 monograph, On the Constitutional and Local Effects of Disease of the Supra-renal Capsules, published in London. In it Addison drew together a small series of patients who shared a characteristic syndrome — “general languor and debility, feebleness of the heart's action, irritability of the stomach, and a peculiar change of colour in the skin” — and linked it to destruction of the adrenal glands found at autopsy. The bronze or smoky discolouration of the skin was so distinctive that the condition was for a time popularly called “bronzed skin disease.”

The monograph was slim (around 39 pages) and beautifully illustrated with colour plates, but its reception was muted at first; the idea that two obscure, ductless glands could be essential to life ran ahead of the physiology of the day. Its importance was quickly grasped on the Continent, however, and within a few years Addison's small book was recognized as one of the foundational documents of endocrinology — arguably the first clear demonstration that a specific gland's destruction produced a specific, predictable, fatal disease.

Back to Table of Contents

Trousseau and the Naming of the Disease

The eponym — the name “Addison's disease” itself — was not coined by Addison. It was bestowed by the influential French clinician Armand Trousseau (1801–1867) of Paris, who was among the first on the Continent to recognize the importance of Addison's findings and who proposed honouring the discoverer by calling the condition maladie d'Addison (Addison's disease). Trousseau, a noted teacher whose clinical lectures were widely read, attached his patients' adrenal failure to Addison's described syndrome and gave it the discoverer's name; the same Trousseau is also credited with popularizing the eponym for Graves' disease.

This is a useful place to keep three roles distinct, because they are easy to blur. Thomas Addison was the describer — the man who first delineated the clinical-pathological entity. Armand Trousseau supplied the eponym — he named it after Addison but did not discover it. And the cause — what actually destroys the adrenal glands — was a separate question worked out gradually by many hands over the following decades, as the next section describes. Addison himself documented the association with adrenal destruction; the underlying mechanisms (tuberculous infection, and later autoimmunity) were clarified afterward.

Back to Table of Contents

Tuberculosis versus Autoimmune Causes Over Time

In Addison's own series, and for the better part of a century afterward, the commonest cause of the disease he had described was tuberculosis of the adrenal glands. Tuberculosis was the great killer of the nineteenth century, and the bacillus readily seeded the adrenals and slowly destroyed them. Historical reviews record that when adrenal insufficiency was first being characterized, tuberculosis was found at autopsy in the large majority of cases — figures on the order of 70 to 90 percent are commonly cited for that era. Bilateral adrenal destruction by tuberculosis was, for generations, essentially synonymous with Addison's disease.

The picture changed across the twentieth century, and for two linked reasons. First, the arrival of effective antituberculous chemotherapy from the late 1940s onward (streptomycin, then isoniazid and rifampicin) sharply reduced tuberculosis and, with it, tuberculous adrenal failure in wealthy countries. Second, medicine developed the concept of autoimmunity — the immune system mistakenly attacking the body's own tissues. By the mid-twentieth century, researchers had identified an autoimmune adrenalitis in which the immune system destroys the adrenal cortex, often marked by antibodies against the enzyme 21-hydroxylase. As tuberculosis receded, this autoimmune process emerged as the dominant cause in the developed world.

The result is a striking historical inversion. Today, in developed countries, roughly three-quarters to four-fifths of Addison's disease cases are autoimmune in origin, while tuberculosis accounts for a small minority. The autoimmune form frequently travels with other autoimmune conditions (such as autoimmune thyroid disease and type 1 diabetes) as part of the autoimmune polyendocrine syndromes. It is important to note the geography, however: in much of the developing world, where tuberculosis remains common, tuberculosis is still a major cause of Addison's disease. The cause of the disease, in other words, has tracked the epidemiology of tuberculosis itself.

Back to Table of Contents

The Hormone-Replacement Revolution

For the first eighty years after Addison's monograph, the diagnosis was effectively a death sentence. There was no way to replace what the destroyed adrenal cortex no longer made, and patients declined into the wasting, low blood pressure, and ultimately the life-threatening collapse known as adrenal (Addisonian) crisis. The turning point came not from a new operation or a new germ theory but from biochemistry — the isolation and identification of the steroid hormones produced by the adrenal cortex.

Through the 1930s and 1940s, two laboratories on different continents worked out the chemistry of the adrenal cortical hormones. At the Mayo Clinic in the United States, the biochemist Edward Calvin Kendall isolated a series of crystalline compounds from the adrenal cortex, including the one he labelled “compound E,” later named cortisone. Independently, in Switzerland, the chemist Tadeus Reichstein isolated and characterized the same family of adrenal steroids. The clinical bridge was supplied by the Mayo rheumatologist Philip Showalter Hench, who in the late 1940s obtained enough of Kendall's compound to test it in patients — famously first in rheumatoid arthritis, with dramatic effect.

For these “discoveries relating to the hormones of the adrenal cortex, their structure and biological effects,” Kendall, Reichstein, and Hench shared the 1950 Nobel Prize in Physiology or Medicine. The significance for Addison's disease was profound and direct: a patient whose own adrenal cortex had been destroyed could now be given the missing hormones from outside. With glucocorticoid replacement (hydrocortisone, and related steroids) and, later, the salt-retaining hormone mineralocorticoid replacement (fludrocortisone, introduced in the 1950s), a once-uniformly-fatal disease was transformed into a chronic, manageable one. People with Addison's disease who take their replacement hormones can now expect to live full lives — provided they understand and respect the need to increase their dose during illness and stress, and to treat adrenal crisis as the emergency it is.

Back to Table of Contents

The Evolution of Diagnosis

For Addison and his immediate successors, diagnosis was purely clinical and pathological: the syndrome was recognized at the bedside — weakness, weight loss, low blood pressure, salt craving, and the telltale skin and mucous-membrane pigmentation — and confirmed only at autopsy, when the destroyed adrenal glands were found. There was no laboratory test, and the hyperpigmentation (which we now understand is driven by elevated pituitary signalling molecules sharing a precursor with melanocyte-stimulating activity) was the single most useful living clue.

The arrival of hormone measurement in the mid-twentieth century changed everything. Once the adrenal hormones could be identified chemically, it became possible to measure cortisol in the blood and to measure the pituitary hormone ACTH (adrenocorticotropic hormone) that drives the adrenal cortex. In primary adrenal failure (Addison's disease) cortisol is low while ACTH is high — the pituitary shouting at a gland that can no longer answer — a pattern that distinguishes primary adrenal disease from pituitary causes of low cortisol.

The decisive practical test became the ACTH stimulation test (also called the cosyntropin, tetracosactide, or Synacthen test), in which a synthetic fragment of ACTH is injected and the cortisol response measured over the following hour. A diseased adrenal cortex cannot mount the expected rise, confirming the diagnosis. Alongside it, the discovery of 21-hydroxylase autoantibodies gave clinicians a way to identify the autoimmune form specifically and even to detect adrenal autoimmunity before the gland has fully failed. Modern diagnosis thus rests on a logic Addison could not have imagined: not waiting for the autopsy, but measuring the hormones directly and probing the gland's reserve.

Back to Table of Contents

Modern Understanding

Today Addison's disease is understood as primary adrenal insufficiency — the failure of the adrenal cortex to produce its essential steroid hormones, chiefly the glucocorticoid cortisol and the mineralocorticoid aldosterone. It sits within a broader family of adrenal insufficiency that also includes secondary causes (a failing pituitary that under-stimulates healthy adrenals) and drug-induced suppression from long-term steroid therapy; strictly, “Addison's disease” refers to disease of the adrenal gland itself. The modern leading cause in developed countries is autoimmune adrenalitis; worldwide, tuberculosis and other infections, adrenal haemorrhage, certain genetic and metabolic disorders, and cancers also figure.

The historical sweep is worth pausing on. In 1855 the disease was a fatal mystery attached to two glands whose purpose was unknown. Within a century it had become a defined endocrine disorder with an identified mechanism, a blood test, and a hormone replacement that turned it survivable. That trajectory — from autopsy curiosity to manageable chronic condition — is one of the cleaner success stories in the history of internal medicine, and it is essentially the story of endocrinology in miniature.

The best-known patient in that story is John F. Kennedy. The future U.S. president was diagnosed with Addison's disease in 1947, during a visit to England where he collapsed and was admitted in adrenal crisis; the diagnosis was kept private for political reasons and managed for years with steroid replacement. His case — thoroughly documented in the later medical and historical literature — is a vivid illustration of the transformation wrought by hormone therapy: a disease that had been a death sentence in Addison's century was, by Kennedy's, compatible with the most demanding public life imaginable. (His was not the only diagnosis in his complex medical history, but Addison's disease is the one for which he is medically famous.)

Back to Table of Contents

Legacy and a Famous Patient

Thomas Addison received only limited recognition in his own lifetime, and he died in 1860, a few years after the monograph that would secure his name. Yet his small book proved one of the seeds of an entire discipline. By demonstrating that destruction of a specific gland produced a specific constitutional disease, he helped establish the central idea of endocrinology: that ductless glands secrete substances essential to the working of the whole body. When, decades later, those substances were isolated and named hormones, Addison's clinical insight was vindicated in chemical terms.

His legacy is doubly inscribed in medical vocabulary. Addison's disease remains the standard name for primary adrenal insufficiency, and Addisonian crisis the standard name for its life-threatening acute decompensation; the bronzing he described is still taught as a classic physical sign. Through Trousseau's eponym, a London diagnostician of the 1850s is invoked daily in clinics and emergency departments worldwide. And the institution he served, Guy's Hospital, honours him among its “giants” alongside Bright and Hodgkin — a trio whose names are stitched permanently into the language of medicine.

The arc of the disease is, finally, a humane one. Addison could only describe and predict a death he could not prevent. The biochemists of the mid-twentieth century — Kendall, Reichstein, Hench — supplied what he could not: a way to give back the hormones the body had lost. Between them, the describer and the chemists turned a uniformly fatal mystery into a condition that a person can live with for a normal lifetime. That is the through-line of this history, and the reason Addison's name is remembered not as a footnote but as a beginning.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical and clinical sources with curated PubMed topic-search links into the literature on Addison's disease, its causes, its diagnosis, and the discovery of the adrenal cortical hormones. Addison's own 1855 monograph and his 1849 note are named in the article as historical primary sources. Each external link opens in a new tab; PubMed links point to the U.S. National Library of Medicine.

Pearce JMS. Thomas Addison (1793–1860). Journal of the Royal Society of Medicine. 2004;97(6):297–300. — doi:10.1177/014107680409700615
Bishop PMF. The history of the discovery of Addison's disease. — PubMed: history of the discovery of Addison's disease
Ten S, New M, Maclaren N. Addison's disease 2001. Journal of Clinical Endocrinology & Metabolism. 2001;86(7):2909–2922. — doi:10.1210/jcem.86.7.7636
Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2016;101(2):364–389. — doi:10.1210/jc.2015-1710
Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. The Lancet. 2014;383(9935):2152–2167. — doi:10.1016/S0140-6736(13)61684-0
Løvås K, Husebye ES. Addison's disease. The Lancet. 2005;365(9476):2058–2061. — doi:10.1016/S0140-6736(05)66700-1
Hench PS. The Nobel Lecture: the reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone (1950). — NobelPrize.org: Hench Nobel Lecture, 1950
The Nobel Prize in Physiology or Medicine 1950 (Kendall, Reichstein, Hench) — NobelPrize.org: 1950 Prize summary
Adrenal tuberculosis as a cause of Addison's disease — PubMed: Addison's disease and adrenal tuberculosis
Autoimmune Addison's disease and 21-hydroxylase autoantibodies — PubMed: autoimmune Addison's disease, 21-hydroxylase
The ACTH (cosyntropin / Synacthen) stimulation test in adrenal insufficiency — PubMed: ACTH stimulation test for adrenal insufficiency
Mandel LR. Endocrine and autoimmune aspects of the health history of John F. Kennedy. Annals of Internal Medicine. 2009;151(5):350–354. — doi:10.7326/0003-4819-151-5-200909010-00011
Kong MF, Jeffcoate W. Eighty-six cases of Addison's disease. Clinical Endocrinology. 1994;41(6):757–761. — doi:10.1111/j.1365-2265.1994.tb02790.x
Changing aetiology and epidemiology of Addison's disease over time — PubMed: Addison's disease epidemiology and aetiology

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents